Christopher Heery, the CHIEF MEDICAL OFFICER of $ACLX, sold 3,343 shares of the company on 09-18-2025 for an estimated $267,468. We received data on the trade from a recent SEC filing. This was a sale of approximately 8.9% of their shares of this class of stock. Following this trade, they now own 34,427 shares of this class of $ACLX stock.
$ACLX Insider Trading Activity
$ACLX insiders have traded $ACLX stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $ACLX stock by insiders over the last 6 months:
- MICHELLE GILSON (CHIEF FINANCIAL OFFICER) has made 0 purchases and 2 sales selling 12,235 shares for an estimated $784,776.
- KAVITA PATEL has made 0 purchases and 4 sales selling 6,000 shares for an estimated $371,235.
- CHRISTOPHER HEERY (CHIEF MEDICAL OFFICER) has made 0 purchases and 2 sales selling 3,643 shares for an estimated $291,468.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ACLX Hedge Fund Activity
We have seen 90 institutional investors add shares of $ACLX stock to their portfolio, and 138 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC removed 527,764 shares (-72.7%) from their portfolio in Q2 2025, for an estimated $34,753,259
- BLACKROCK, INC. removed 499,385 shares (-12.6%) from their portfolio in Q2 2025, for an estimated $32,884,502
- DECHENG CAPITAL LLC added 497,609 shares (+995.2%) to their portfolio in Q2 2025, for an estimated $32,767,552
- JANUS HENDERSON GROUP PLC removed 486,912 shares (-32.2%) from their portfolio in Q2 2025, for an estimated $32,063,155
- PERCEPTIVE ADVISORS LLC removed 448,478 shares (-15.3%) from their portfolio in Q2 2025, for an estimated $29,532,276
- PRICE T ROWE ASSOCIATES INC /MD/ removed 400,851 shares (-21.8%) from their portfolio in Q2 2025, for an estimated $26,396,038
- PICTET ASSET MANAGEMENT HOLDING SA added 377,649 shares (+6882.6%) to their portfolio in Q2 2025, for an estimated $24,868,186
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ACLX Analyst Ratings
Wall Street analysts have issued reports on $ACLX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Scotiabank issued a "Sector Outperform" rating on 07/31/2025
- Citigroup issued a "Buy" rating on 06/17/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/16/2025
To track analyst ratings and price targets for $ACLX, check out Quiver Quantitative's $ACLX forecast page.
$ACLX Price Targets
Multiple analysts have issued price targets for $ACLX recently. We have seen 3 analysts offer price targets for $ACLX in the last 6 months, with a median target of $115.0.
Here are some recent targets:
- George Farmer from Scotiabank set a target price of $133.0 on 07/31/2025
- Geoff Meacham from Citigroup set a target price of $110.0 on 06/17/2025
- Emily Bodnar from HC Wainwright & Co. set a target price of $115.0 on 06/16/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
